Polymorphisms predicted to alter function in Prostaglandin E2 synthase and Prostaglandin E2 receptors

Pharmacogenetics and Genomics

Volumn 17, Issue 3, 2007, Pages 221-227

  Bigler, Jeannette ^a,b   Sibert, Justin G ^a   Poole, Elizabeth M ^a   Carlson, Christopher S ^a   Potter, John D ^a   Ulrich, Cornelia M ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b AMGEN INC   (United States)

Author keywords

Colorectal cancer; Polymorphism; Prostaglandin E2 receptor; Prostaglandin E2 synthase

Indexed keywords

PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E SYNTHASE; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAGLANDIN E4; UNCLASSIFIED DRUG;

AFRICAN AMERICAN; ARTICLE; CAUCASIAN; GENE SEQUENCE; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN FUNCTION; SEQUENCE HOMOLOGY;

AFRICAN CONTINENTAL ANCESTRY GROUP; AMINO ACID SUBSTITUTION; BASE SEQUENCE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FORECASTING; GENE FREQUENCY; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; POLYMORPHISM, GENETIC; RECEPTORS, PROSTAGLANDIN E; SEQUENCE ANALYSIS, PROTEIN; SEQUENCE HOMOLOGY, AMINO ACID; SOFTWARE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34247587047     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3280119d50     Document Type: Article

References (33)

1. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils, and pharmacogenetics. Nat Rev Cancer 2006; 6:130-140.
2. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348:891-899.
3. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348:883-890.
4. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 1998; 90:1609-1620.
5. Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB, Whelan J. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+ ) mice. Cancer Res 2002; 62:403-408.
6. Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B, et al. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 2004; 6:285-295.
7. Bennett A, Civier A, Hensby CN, Melhuish PB, Stamford IF. Measurement of arachidonate and its metabolites extracted from human normal and malignant gastrointestinal tissues. Gut 1987; 28:315-318.
8. Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003; 278:35451-35457.
9. Pugh S, Thomas GA. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut 1994; 35:675-678.
10. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122:518-523.
11. Giardiello FM, Casero RA Jr, Hamilton SR, Hylind LM, Trimbath JD, Geiman DE, et al. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis. Gastroenterology 2004; 126:425-431.
12. Shao J, Jung C, Liu C, Sheng H. Prostaglandin E2 Stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer. J Biol Chem 2005; 280:26565-26572.
13. Wang D, Buchanan FG, Wang H, Dey SK, DuBois RN. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Rasmitogen-activated protein kinase cascade. Cancer Res 2005; 65:1822-1829.
14. Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory SA. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 1996; 97:2672-2679.
15. Giagoudakis G, Markantonis SL. Relationships between the concentrations of prostaglandins and the nonsteroidal antiinflammatory drugs indomethacin, diclofenac, and ibuprofen. Pharmacotherapy 2005; 25:18-25.
16. Seppala E, Nissila M, Isomaki H, Nuotio P, Nykanen E, Laitinen O, et al. Comparison of the effects of different anti-inflammatory drugs on synovial fluid prostanoid concentrations in patients with rheumatoid arthritis. Clin Rheumatol 1985; 4:315-320.
17. Winde G, Schmid KW, Schlegel W, Fischer R, Osswald H, Bunte H. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal antiinflammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum 1995; 38:813-830.
18. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 2001; 108:25-30.
19. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 2004; 103:147-166.
20. Poole E, Bigler J, Whitton J, Potter J, Sibert J, Ulrich C. Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 2006; 15:502-508.
21. Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD, et al. PTGS2 (COX-2) - 765G>C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 2005; 14:616-619.
22. Ulrich CM, Bigler J, Sparks R, Whitton J, Sibert JG, Goode EL, et al. Polymorphisms in PTGS1 ( =COX-1) and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 2004; 13:889-893.
23. Ulrich CM, Bigler J, Sibert J, Greene EA, Sparks R, Carlson CS, et al. Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations. Hum Mutat 2002; 20:409-410.
24. Ulrich CM, Kampman E, Bigler J, Schwartz SM, Chen C, Bostick R, et al. Colorectal adenomas and the C677T MTHFR polymorphism: evidence for gene-environment interaction? Cancer Epidemiol Biomarkers Prev 1999; 8:659-668.
25. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res 2001; 11:863-874.
26. Ng PC, Henikoff S. Accounting for human polymorphisms predicted to affect protein function. Genome Res 2002; 12:436-446.
27. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003; 31:3812-3814.
28. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res 2002; 30:3894-3900.
29. Sunyaev S, Ramensky V, Bork P. Towards a structural basis of human non-synonymous single nucleotide polymorphisms. Trends Genet 2000; 16:198-200.
30. Sunyaev S, Ramensky V, Koch I, Lathe W III, Kondrashov AS, Bork P. Prediction of deleterious human alleles. Hum Mol Genet 2001; 10:591-597.
31. Bairoch A, Apweiler R. The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000. Nucleic Acids Res 2000; 28:45-48.
32. Ulrich CM, Carlson CS, Sibert J, Poole EM, Yu JH, Wang LH, et al. Thromboxane synthase (TBXAS1) polymorphisms in African-American and Caucasian populations: evidence for selective pressure. Hum Mutat 2005; 26:394-395.
33. Hinds DA, Stuve LL, Nilsen GB, Halperin E, Eskin E, Ballinger DG, et al. Whole-genome patterns of common DNA variation in three human populations. Science 2005; 307:1072-1079.